- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02105636
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Cordoba, Argentina, 5000
- Local Institution - 0014
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentina, 1880
- Local Institution - 0015
-
-
Tucuman
-
San Miguel De Tucuman, Tucuman, Argentina, 4000
- Local Institution - 0013
-
-
-
-
-
Sao Paulo, Brasil, 01321-001
- Local Institution - 0055
-
-
RIO Grande DO SUL
-
Ijui, RIO Grande DO SUL, Brasil, 98700-000
- Local Institution - 0054
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasil, 90610-000
- Local Institution
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Local Institution - 0038
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- Local Institution - 0045
-
-
-
-
California
-
Stanford, California, Forente stater, 94305
- Stanford University Medical Center
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- H. Lee Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Local Institution - 0001
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60637
- Local Institution - 0002
-
-
Louisiana
-
Metairie, Louisiana, Forente stater, 70006
- Local Institution - 0004
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Forente stater, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University of Michigan
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- DUMC
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Local Institution - 0012
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Local Institution - 0007
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt Cancer Clinic
-
-
Texas
-
Hoston, Texas, Forente stater, 77030
- Univ Of Tx. Md Anderson
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Local Institution - 0031
-
-
-
-
-
Lyon Cedex 08, Frankrike, 69373
- Local Institution
-
Nice Cedex 2, Frankrike, 06189
- Local Institution
-
Villejuif Cedex, Frankrike, 94805
- Local Institution
-
-
-
-
-
Hong Kong, Hong Kong
- Local Institution
-
-
-
-
-
Milano, Italia, 20142
- Local Institution
-
Napoli, Italia, 80131
- Local Institution
-
Padova, Italia, 35128
- Local Institution
-
-
FC
-
Meldola, FC, Italia, 47014
- Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori
-
-
MI
-
Milano, MI, Italia, 20133
- Local Institution
-
-
TO
-
Torino, TO, Italia, 10126
- Local Institution
-
-
-
-
-
Akashi, Hyogo, Japan, 673-8558
- Local Institution - 0057
-
Tokyo, Japan, 135-8550
- Local Institution - 0061
-
-
Aichi
-
Nagoya, Aichi, Japan, 4648681
- Local Institution - 0056
-
-
Chiba
-
Kashiwa, Chiba, Japan, 2778577
- Local Institution - 0060
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 0608648
- Local Institution - 0062
-
-
Hyogo
-
Kobe-shi, Hyogo, Japan, 650-0017
- Local Institution - 0058
-
-
Osaka
-
Takatsuki, Osaka, Japan, 5698686
- Local Institution - 0063
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japan, 4118777
- Local Institution - 0059
-
-
-
-
-
Seoul, Korea, Republikken, 135-710
- Local Institution - 0067
-
Seoul, Korea, Republikken, 137-701
- Local Institution - 0066
-
-
-
-
-
Amsterdam, Nederland, 1081 HV
- Local Institution
-
Groningen, Nederland, 9713 AP
- Local Institution
-
Leiden, Nederland, 2333 ZA
- Local Institution
-
-
-
-
-
Barcelona, Spania, 08035
- Local Institution - 0032
-
Barcelona, Spania, 08036
- Local Institution - 0035
-
Madrid, Spania, 28041
- Local Institution - 0034
-
Valencia, Spania, 46010
- Local Institution - 0033
-
-
-
-
-
Surrey, Storbritannia, SM2 5PT
- Local Institution
-
-
Greater London
-
London, Greater London, Storbritannia, SW3 6JJ
- Local Institution
-
-
Greater Manchester
-
Manchester, Greater Manchester, Storbritannia, M20 4BX
- Local Institution
-
-
Hampshire
-
Southampton, Hampshire, Storbritannia, SO16 6YD
- Local Institution
-
-
Merseyside
-
Wirral, Merseyside, Storbritannia, CH63 4JY
- Local Institution
-
-
-
-
-
Zuerich, Sveits, 8091
- Local Institution - 0051
-
-
-
-
-
Tainan, Taiwan, 704
- Local Institution - 0065
-
Taipei, Taiwan, 100
- Local Institution - 0064
-
-
-
-
-
Berlin, Tyskland, 12200
- Local Institution - 0047
-
Bonn, Tyskland, 53127
- Local Institution - 0049
-
Essen, Tyskland, 45122
- Local Institution - 0048
-
Hamburg, Tyskland, 20246
- Local Institution - 0052
-
Hannover, Tyskland, 30625
- Local Institution - 0046
-
Wuerzburg, Tyskland, 97070
- Local Institution - 0050
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Men and women ≥ 18 years of age with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Histologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)
- Tumor progression or recurrence within 6 months of last dose of platinum therapy in the adjuvant (ie with radiation after surgery), primary (ie, with radiation), recurrent, or metastatic setting
- Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria
Exclusion Criteria:
- Active brain metastases or leptomeningeal metastases are not allowed
- Histologically confirmed recurrent or metastatic carcinoma of the nasopharynx, squamous cell carcinoma of unknown primary, and salivary gland or non-squamous histologies (eg: mucosal melanoma) are not allowed
- Subjects with active, known or suspected autoimmune disease
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Arm A: Nivolumab
Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
|
Andre navn:
|
Aktiv komparator: Arm B: Cetuximab/Methotrexate/Docetaxel
Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression OR Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression OR Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival (OS)
Tidsramme: From date of randomization to date of death (Up to approximately 18 months)
|
OS was defined as the time from randomization to the date of death from any cause.
Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.
Median OS time was calculated using Kaplan-Meier (KM) method.
|
From date of randomization to date of death (Up to approximately 18 months)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Investigator-Assessed Progression-Free Survival (PFS)
Tidsramme: From date of randomization to date of disease progression or death, whichever occurs first (Up to approximately 87 months)
|
PFS was defined as the time between the date of randomization and the first date of documented progression, as determined by the investigator (as per Response Evaluation Criteria In Solid Tumors (RECIST1.1)), or death due to any cause, whichever occurs first. Progressive Disease: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must demonstrate an absolute increase of at least 5mm. Participants who:
|
From date of randomization to date of disease progression or death, whichever occurs first (Up to approximately 87 months)
|
Investigator-Assessed Objective Response Rate (ORR)
Tidsramme: From date of randomization to date of disease progression or study drug is discontinued, whichever occurs first (Up to approximately 87 months)
|
ORR was defined as the percentage of randomized participants who achieved a best response of complete response (CR) or partial response (PR) using the RECIST1.1 criteria as per investigator assessment.
Complete Response (CR): Disappearance of all target lesions.
Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions.
|
From date of randomization to date of disease progression or study drug is discontinued, whichever occurs first (Up to approximately 87 months)
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck. 2020 Oct;42(10):2852-2862. doi: 10.1002/hed.26331. Epub 2020 Jun 24.
- Saba NF, Blumenschein G Jr, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncol. 2019 Sep;96:7-14. doi: 10.1016/j.oraloncology.2019.06.017. Epub 2019 Jul 3.
- Cocks K, Contente M, Simpson S, DeRosa M, Taylor FC, Shaw JW. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck. Pharmacoeconomics. 2019 Aug;37(8):1041-1047. doi: 10.1007/s40273-019-00798-1.
- Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040). J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.
- Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Sum Kenneth Li W, Ferris RL, Gillison M, Namba Y, Monga M, Lynch M, Tahara M. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol. 2017 Oct;73:138-146. doi: 10.1016/j.oraloncology.2017.07.023. Epub 2017 Sep 1.
- Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grunwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.
- Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter histologisk type
- Neoplasmer
- Neoplasmer etter nettsted
- Neoplasmer, kjertel og epitel
- Neoplasmer i hode og nakke
- Neoplasmer, plateepitelceller
- Karsinom
- Karsinom, plateepitel
- Plateepitelkarsinom i hode og nakke
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Antirevmatiske midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, immunologiske
- Dermatologiske midler
- Immune Checkpoint-hemmere
- Reproduktive kontrollmidler
- Abortfremkallende midler, ikke-steroide
- Aborterende midler
- Folsyreantagonister
- Docetaxel
- Nivolumab
- Metotreksat
- Cetuximab
Andre studie-ID-numre
- CA209-141
- 2013-003622-86 (EudraCT-nummer)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Docetaxel
-
Tianjin Medical University Cancer Institute and...Rekruttering
-
Zhuhai Beihai Biotech Co., LtdFullførtSolide svulster | Bioekvivalens | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaFullførtIkke-småcellet lungekreft (NSCLC)Kina
-
Optimal Health ResearchFullførtBrystkreft | Lungekreft | ProstatakreftForente stater
-
Fudan UniversityHar ikke rekruttert ennåAvansert ikke-småcellet lungekreft
-
Hunan Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.; Hunan Provincial People...UkjentIkke-småcellet lungekreftKina
-
Seoul National University HospitalClinical Research Center for Solid Tumor, KoreaAvsluttetPlateepitelkarsinom i hode og nakkeKorea, Republikken
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaAvsluttetIkke plateepitel, ikke småcellet lungeKina
-
University of OxfordUkjent